79935
document
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate ( Estracyt ) or conventional estrogen . A follow-up of 212 randomized patients . Two hundred and twelve patients treated for prostatic cancer grade I or II were investigated for cardiovascular complications . The patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate ( Estracyt ) or polyestradiol phosphate and ethinyl estradiol . Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease , venous thromboembolism , cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment . Among the patients getting cardiovascular complications , these occurred within two months after the start of treatment in 50 % and within one year in 85 % of them . There was a statistically significant correlation between the incidence of cardiovascular complications and a history of previous cardiovascular disease . This criterion was however in retrospect found to predict cardiovascular complications in only 67 of the 126 patients getting one or several of these complications .
79936
Intervention_Pharmacological
estramustine phosphate ( Estracyt )
79937
Intervention_Pharmacological
conventional estrogen
79938
Intervention_Pharmacological
estramustine phosphate ( Estracyt )
79939
Intervention_Pharmacological
polyestradiol phosphate and ethinyl estradiol
79940
Outcome_Physical
ischemic heart disease
79941
Outcome_Physical
venous thromboembolism
79942
Outcome_Physical
cardiac incompensation
79943
Outcome_Physical
cerebral depression
79944
Outcome_Adverse-effects
incidence of cardiovascular complications
79945
Outcome_Physical
cardiovascular complications
79946
Participant_Condition
prostate cancer
79947
Participant_Condition
follow-up of 212 randomized patients .